Therapeutic effect of Qingyi decoction in severe acute pancreatitis-induced intestinal barrier injury

Jing-Wen Zhang, Gui-Xin Zhang, Hai-Long Chen, Ge-Liang Liu, Lawrence Owusu, Yu-Xi Wang, Guan-Yu Wang, Cai-Ming Xu

Jing-Wen Zhang, Gui-Xin Zhang, Hai-Long Chen, Lawrence Owusu, Yu-Xi Wang, Guan-Yu Wang, Cai-Ming Xu, Department of Surgery, The First Affiliated Hospital, Dalian Medical University, Dalian 116011, Liaoning Province, China; Ge-Liang Liu, Yu-Xi Wang, Department of Surgery, The Second Affiliated Hospital, Dalian Medical University, Dalian 116023, Liaoning Province, China.

Author contributions: Zhang JW, Zhang GX, and Chen HL designed the research; Zhang JW and Liu GL performed the experiments; Wang YX, Wang GY, Owusu L, and Xu CM analyzed the data; Zhang JW and Owusu L drafted the paper; all authors read, contributed to and approved the final version to be published; Zhang JW and Zhang GX contributed equally to the work and should be regarded as co-first authors.

Supported by National Natural Science Foundation of China, No. 81173452.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Correspondence to: Hai-Long Chen, PhD, Professor of Medicine, Department of Surgery, The First Affiliated Hospital, Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. hailongchen2007@163.com

Telephone: +86-411-83600680; Fax: +86-411-83631294

Received: August 31, 2014; Peer-review started: September 1, 2014; First decision: October 14, 2014; Revised: November 6, 2014; Accepted: December 20, 2014; Article in press: December 22, 2014; Published online: March 28, 2015.

Abstract

AIM: To investigate the effect of Qingyi decoction on the expression of secreted phospholipase A2 (sPLA2) in intestinal barrier injury.

METHODS: Fifty healthy Sprague-Dawley rats were randomly divided into control, severe acute pancreatitis (SAP), Qingyi decoction-treated (QYT), dexamethasone-treated (DEX), and verapamil-treated (VER) groups. The SAP model was induced by retrograde infusion of 1.5% sodium deoxycholate into the biliopancreatic duct of the rats. All rats were sacrificed 24 h post-SAP induction. Arterial blood, intestine, and pancreas from each rat were harvested for investigations. The levels of serum amylase (AMY) and diamine oxidase (DAO) were determined using biochemical methods, and serum tumor necrosis factor (TNF)-α level was measured by an enzyme linked immunosorbent assay. Pathologic changes in the harvested tissues were investigated by microscopic examination of hematoxylin and eosin-stained tissue sections. The expressions of sPLA2 at mRNA and protein levels were detected by reverse transcriptase PCR and Western blot, respectively. A terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay was used to investigate apoptosis of epithelial cells in the intestinal tissues.

RESULTS: Compared to the control group, the expression of sPLA2 at both the mRNA and protein levels increased significantly in the SAP group (0.36 ± 0.13 vs 0.90 ± 0.38, and 0.16 ± 0.05 vs 0.64 ± 0.05, respectively; Ps < 0.01). The levels of AMY, TNF-α and DAO in serum were also significantly increased (917 ± 62 U/L vs 6870 ± 810 U/L, 59.7 ± 14.3 ng/L vs 180.5 ± 20.1 ng/L, and 10.37 ± 2.44 U/L vs 37.89 ± 5.86 U/L, respectively; Ps < 0.01). The apoptosis index of intestinal epithelial cells also differed significantly between the SAP and control rats (0.05 ± 0.02 vs 0.26 ± 0.06; P < 0.01). The serum levels of DAO and TNF-α, and the intestinal apoptosis index significantly correlated with sPLA2 expression in the intestine (r = 0.895, 0.893 and 0.926, respectively; Ps < 0.05).

The
levels of sPLA₂, AMY, TNF-α, and DAO in the QYT, VER, and DEX groups were all decreased compared with the SAP group, but not the control group. Qingyi decoction intervention, however, gave the most therapeutic effect against intestinal barrier damage, although the onset of its therapeutic effect was slower.

CONCLUSION: Qingyi decoction ameliorates acute pancreatitis-induced intestinal barrier injury by inhibiting the overexpression of intestinal sPLA₂. This mechanism may be similar to that of verapamil.

Key words: Intestinal barrier injury; Qingyi decoction; Secreted phospholipase A₂; Severe acute pancreatitis; Verapamil

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Secreted phospholipase A₂ (sPLA₂) is a damage factor that stimulates excessive inflammatory responses, which can lead to the degradation and hydrolysis of biologic membranes, thus promoting epithelial injury. We demonstrate that sPLA₂ is overexpressed at the mRNA and protein levels in a rat model of severe acute pancreatitis-induced intestinal barrier injury. However, a traditional Chinese medicine, Qingyi decoction, effectively antagonized this overexpression of sPLA₂ to alleviate the severity of the disease. This observation was comparable to the inhibitory effect of verapamil on sPLA₂ expression.


INTRODUCTION
Severe acute pancreatitis (SAP) is a common surgical acute abdominal disease and can lead to the early death of patients because of associated systemic inflammatory response syndrome and multiple organ dysfunction syndrome[1]. One severe complication is often intestinal barrier damage. This permits great quantities of gut bacteria and endotoxin to enter the blood and lymphatic circulations, and eventually whole internal organs[2]. Also, the body's mononuclear macrophage system is activated, which leads to release of large quantities of tumor necrosis factor (TNF), interferons, interleukins, and other inflammatory factors to trigger cascade of inflammatory events that further cause tissue damage[3,4].

Secreted phospholipase A₂ (sPLA₂), the main phospholipase A subtype, is a damage factor whose function depends on intracellular calcium ion concentration. Under the stimulus of excessive sPLA₂ expression, large amounts of inflammatory factors cause the degradation of cell surface active substances and hydrolyze biologic membranes to aggravate lecithin damage in organs and tissues[5,6]. The efficacy of the Chinese medicine Qingyi decoction (QYT) has been demonstrated through clinical practice and animal experiments for years; QYT is an effective prescription for the treatment of acute pancreatitis[6]. It is generally well tolerated by patients, and induces purgation, promotes blood circulation, eliminates blood stasis, and reduces inflammation. It can also directly neutralize endotoxins and protect the intestinal barrier.

In our previous study on the intervening role of QYT in patients following acute pancreatitis, it was shown that QYT administration reduced lung injury by decreasing the transcription of sPLA₂, thereby protecting pulmonary function[6].

Dexamethasone (DEX) is a glucocorticoid with several beneficial functions including anti-inflammatory activity, microcirculation promotion, and oxygen free radical scavenging. Verapamil (VER) can effectively reduce tissue damage, especially intestinal damage, by reducing intracellular calcium ion concentration which plays a decisive role in sPLA₂ activation[7]. VER is a commonly used calcium blocker. Considering its inhibitory effect on sPLA₂, VER may be used to protect against intestinal tissue and pancreatic injuries during SAP.

The present study aimed to examine the role of sPLA₂ in a rat model of SAP-induced intestinal barrier injury and the intervening roles of QYT and VER.

MATERIALS AND METHODS

Animals and grouping
Fifty clean-grade healthy male Sprague-Dawley rats (180-220 g, age: 8 wk) were purchased from the specific-pathogen-free Animal Center of Dalian Medical University (Dalian, China). The animals were randomly divided into five groups (n = 10 per group): controls, untreated SAP, and SAP treated with QYT (Chinese Medicine Preparations Division, First Affiliated Hospital of Dalian Medical University, Dalian, China, Supplementary 1), DEX (Ling Rui Pharmaceutical, Zhengzhou, China), or VER (Harvest Pharmaceutical, Shanghai, China). This study was carried out in strict accordance with the recommendations in the European Union Animal Management Practices (1986). The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Dalian Medical University (Dalian, China).

Model preparation
The SAP intestinal barrier damage model was established using bile pancreatic duct retrograde injection of 1.5%
At 24 h post-operation, animals were anesthetized and diamine mixture, mixed, and incubated for 20 s, and reduced coenzyme, glutamate dehydrogenase, 1.4 d was added to 800 µL of detection reagent (Tris-HCl, 10 mM, and diamine oxidase, α-phenyl-2-thiourea (PMSF) (all purchased from Keygen, Nanjing, China) for protein extraction. Under sterile conditions, the needle of a 1 mL syringe was inserted into the major duodenal papilla of the rat and 1.5% deoxycholic acid sodium salt (1 mL/kg dose, speed of 0.1 mL/min) was injected through the bile pancreatic duct into the pancreas. The control group only had their pancreas marginally rotated to avoid any incidence of mild acute pancreatitis that could arise following the injection of the solvent (water) used to dissolve the salt. The very short time (24 h) required for the manifestation of chemically induced SAP would not permit complete resolution of such mild acute pancreatitis in the control rats, which would in turn compromise the principal clinical differences between the control and the SAP groups. The DEX group (10 mg/kg body weight/dose, 5 mg/mL concentration) and VER group (1.25 mg/kg body weight/dose, 2.5 mg/mL concentration) were given their respective drugs intravenously immediately, 6 and 12 h post-operation. The QYT group, however, was orally treated with QYT (10 mL/kg body weight/dose) 0.5 h before the induction of SAP (to permit enough time for the absorption of the traditional drug into the blood), and then 6 and 12 h post-operation. At 24 h post-operation, animals were anesthetized and abdominal aortic blood was taken for serum collection and storage at -80°C until use. The pancreas and intestinal tissues were harvested, and part of each was either immediately stored at -80°C or fixed in neutral phosphate formaldehyde.

Pathologic observation
Pathologic observations were made under an optical microscope (Leica DMIRB; Leica, Solms, Germany). Pancreas and intestinal tissues previously fixed in neutral phosphate formaldehyde were paraffin embedded and sectioned (2 µm serial sectioning) for pathologic morphology observation after routine hematoxylin and eosin staining.

Serum amylase, TNF-α, and diamine oxidase measurement
Serum amylase content was determined using a fully automatic biochemical analyzer (Abbott Laboratories, ML, United States) from 50 µL of rat serum that was diluted six times with MilliQ (Millipore Corp, Billerica, MA, United States) water before acquisition.

Serum TNF-α level was determined using an enzyme-linked immunosorbent assay kit (Lengtion Company, Shanghai, China) according to the manufacturer’s instructions.

For diamine oxidase (DAO) detection, 80 µL of serum was added to 800 µL of detection reagent (Tris-HCl, reduced coenzyme, glutamate dehydrogenase, 1.4 d diamine mixture), mixed, and incubated for 20 s, and absorbance was read at 340 nm wavelength for the value of A1. The mixture was placed in a water bath (37°C) for 10 min, and then the absorbance at 340 nm was read again for the A2 value. The DAO activity (U/L) = {{[A1 × A2]/[A2 × cuvette diameter (cm) × 6.3 × NADH mmol extinction coefficient] × [reaction liquid volume (µL)/sample volume (µL)]}} × 1000.

Detection of intestinal epithelial cell apoptosis
A terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay kit (Keygen, Nanjing, China) was used to detect apoptosis of epithelial cells in paraffin-embedded intestinal tissues according to the manufacturer's instructions. Under high magnification (200 ×), five randomly selected areas were observed. The apoptosis index (AI) was calculated as the percentage of fluorescein isothiocyanate-positive cells out of 500 intestinal epithelial cells.

Quantitative PCR assessment of intestinal sPLA2 mRNA expression
Total RNA was extracted from intestinal tissue using RNAisoPlus (Takara Bio Inc., Otsu, Shiga, Japan) according to the manufacturer’s instructions. Briefly, 1 mL of RNAisoPlus was added to 50 mg of tissue and homogenized on ice. Then 200 µL of chloroform was added and the mixture centrifuged before the supernatant was collected. Isopropyl alcohol was used to precipitate the RNA from the chloroform. Precipitated RNA was dissolved in RNase-free water and its quality measured using an ultraviolet spectrophotometer. The observed values of A260/280 ranged between 1.8 and 2.0. The routine PCR condition included 30 cycles at an annealing temperature of 60°C for 30 s. Primers (Takara) were as follows: sPLA2, 5’-GTGCAGGATCCCCAAGG-3’ (upstream), 5’-GCACTGGCGTGTTCCCTCAG-3’ (downstream), product length, 283 bp; and β-actin, 5’-GAGTCTGTGCGATCACCAG-3’ (upstream), 5’-CTAGAGGATTTCGCGTGA-3’ (downstream), product length, 531 bp. An ultraviolet imaging system (Protein Simple; Alphalmade HP, Santa Clara, CA, United States) was used to read the PCR products after agarose gel electrophoresis. Intestinal tissue sPLA2 mRNA expression level was estimated as the ratio of intestinal sPLA2 mRNA gray value to its corresponding internal control (β-actin) grey value.

Western blotting for intestinal tissue sPLA2 protein expression
Total protein was extracted using 1 mL of RIPA lysis buffer supplemented with 1 µL protease inhibitor solution, 5 µL PMSF and 10 µL phosphatase inhibitor (all purchased from Keygen, Nanjing, China) for every 100 mg of intestinal tissue; protein (100 µg) from each sample was separated on SDS-PAGE and transferred onto a nitrocellulose membrane. Sections of the membrane were cut according to the estimated
Zhang JW et al. Qingyi decoction and intestinal barrier injury
Pancreatic and intestinal tissue histopathology

Substantial pathologic changes were observed in the pancreatic and intestinal tissues from each group of rats except the control group, where mucosal lobular structures did not exhibit edema or bleeding. Other features observed in the disease groups included blurred SAP pancreas lobular structures, large numbers of inflammatory cell infiltration, extensive hemorrhaging, and intestinal epithelial cell necrosis of > 50%. However, the pathologic damage in QYT, DEX, and VER groups was greatly reduced compared to the SAP group. The QYT and VER groups exhibited intestinal mucosal epithelial cell swelling, generally of normal morphology, whereas the DEX group, in addition to cell swelling deformation, showed varying degrees of inflammatory cell infiltration. Their pancreatic lobular structures were clear with only a small amount of edema, hemorrhage, and inflammatory cell invasion. Necrotic areas were the smallest compared to the DEX and SAP groups (Figure 1).

Serum levels

Compared with the control group, serum AMY levels in the SAP rats significantly increased ($P < 0.01$) (Table 1). However, serum AMY levels in the treated (QYT, DEX or VER) groups were significantly lower compared with the SAP group ($P < 0.05$). Furthermore, serum TNF-α levels were significantly elevated in the SAP group compared to controls ($P < 0.01$). The serum TNF-α levels significantly decreased in the SAP rats following QYT, DEX, or VER intervention ($Ps < 0.05$). Serum DAO levels in the SAP group were significantly higher than controls ($P < 0.01$). Compared with the SAP group, levels of serum DAO in the QYT, DEX and VER groups decreased significantly ($Ps < 0.05$).

Intestinal epithelial cell apoptosis

The intestinal epithelial cell AI in the SAP group was significantly higher compared with controls ($P < 0.01$). However, compared with the SAP group, the AIs of the QYT, DEX, or VER groups were significantly lower ($Ps < 0.05$). The AI of the QYT group was the most reduced among the treated cohort (Table 1) (Figure 2).

<table>
<thead>
<tr>
<th>Group ($n = 12$)</th>
<th>AMY (U/L)</th>
<th>TNF-α (ng/L)</th>
<th>DAO (U/L)</th>
<th>AI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>917 ± 62</td>
<td>59.7 ± 14.3</td>
<td>10.37 ± 2.44</td>
<td>0.05 ± 0.02</td>
</tr>
<tr>
<td>SAP</td>
<td>6670 ± 810a</td>
<td>180.5 ± 20.1a</td>
<td>37.89 ± 5.86a</td>
<td>0.26 ± 0.06a</td>
</tr>
<tr>
<td>QYT</td>
<td>4048 ± 511a</td>
<td>122.4 ± 15.2a</td>
<td>22.43 ± 2.13a</td>
<td>0.13 ± 0.04a</td>
</tr>
<tr>
<td>DEX</td>
<td>3363 ± 200a</td>
<td>137.0 ± 23.4a</td>
<td>24.27 ± 3.36a</td>
<td>0.16 ± 0.03a</td>
</tr>
<tr>
<td>VER</td>
<td>3852 ± 234a</td>
<td>125.2 ± 16.5a</td>
<td>26.96 ± 5.56a</td>
<td>0.19 ± 0.03a</td>
</tr>
</tbody>
</table>

AMY: Serum amylase; TNF: Tumor necrosis factor; DAO: Diamine oxidase index; SAP: Severe acute pancreatitis; QYT: Qingyi decoction; DEX: Dexamethasone; VER: Verapamil; $a^2P < 0.05$ vs SAP; $b^2P < 0.01$ vs controls.

Table 1  Serum amylase, tumor necrosis factor-α, and diamine oxidase levels, and apoptosis index of the different experimental groups

**RESULTS**

**Statistical analysis**

Statistical analysis was conducted using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, United States). All data are reported as mean ± SD, and analysis of variance was used for comparisons among the groups. A $P < 0.05$ was considered statistically significant. The Pearson product-moment correlation was used for correlation analysis.

**Figure 1  Pathologic changes in the pancreatic and intestinal tissues of the experimental model groups.** Pancreatic tissue in A: Control; B: Severe acute pancreatitis (SAP); C: SAP treated with Qingyi decoction (QYT); D: SAP treated with dexamethasone (DEX); and E: SAP treated with verapamil (VER) rats. Intestinal tissue in F: Control; G: SAP; H: QYT-treated; I: DEX-treated; and J: VER-treated rats (hematoxylin and eosin, 100 ×).
sPLA2 mRNA expression in intestinal tissue

Compared with the control group, intestinal tissue sPLA2 mRNA expression in the SAP group was significantly higher ($P < 0.01$) (Figure 3). The sPLA2 mRNA expression level in the QYT, DEX, and VER groups, however, were significantly lower compared with the SAP group ($Ps < 0.05$).

sPLA2 protein expression in intestinal tissue and correlation analysis

The expression of sPLA2 protein in the intestinal tissue of the SAP group was significantly higher compared with the control group ($P < 0.01$) (Figure 4). Upon intervention with QYT, DEX, or VER in SAP rats, the protein level decreased significantly ($Ps < 0.05$). The inhibition of the sPLA2 protein expression was superior in the QYT treatment group. Nonetheless, the intestinal expression of sPLA2 protein in the QYT, DEX, and VER groups was significantly higher compared with controls ($Ps < 0.05$). The protein expression level of sPLA2 positively correlated with serum TNF-α and DAO levels in the SAP rats ($Ps < 0.05$) (Table 2).

DISCUSSION

sPLA2 is widely present in mammalian tissues and cells, and functions to rebuild phospholipids, transmit signals in cell physiologic processes, and plays an important role in some diseases, such as SAP[7]. Overexpression of sPLA2 promotes a large release of arachidonic acid, prostaglandin, platelet-activating factors, and other bioactive substances[8-10]. Overexpression of sPLA2 is mainly stimulated by a large number of inflammatory mediators, and it is an important factor in intestinal...
ischemia-reperfusion injury\(^{[11,12]}\). sPLA\(_2\) can degrade phospholipid components of cell membranes, and thus directly damage the intestinal mucosa. It can also indirectly cause ischemia-reperfusion injury and deregulate the inflammatory cytokine network, and thus attack the intestinal barrier in the development and progression of SAP\(^{[13-15]}\). The overall consequences include decreased intestinal peristalsis and intestinal epithelial cell apoptosis and necrosis\(^{[16-18]}\). These activities may promote the multiplication of intestinal bacteria and their translocation into the blood, which can cause gut origin sepsis and endotoxemia\(^{[19-21]}\). Destruction of the intestinal mucosa mechanical barrier also results in the release of a large amount of diamine oxidase enzymes and active substances\(^{[22-24]}\). Wilmore et al.\(^{[25]}\) first proposed that intestinal barrier injury may lead to systemic inflammatory response syndrome and multiple organ dysfunction syndrome\(^{[26-30]}\). Therefore, the study of the role of sPLA\(_2\) in the pathogenesis of intestinal barrier damage in SAP is of great significance.

We found that SAP successfully developed in the rats after 24 h of disease induction, characterized by pancreatic and intestinal tissue injury, and pathologic changes. The serum levels of AMY, TNF-\(\alpha\), and DAO significantly increased in the SAP group compared with either the controls or any of the treated groups.
Intestinal epithelial cell apoptosis index and sPLA₂ expression at both the mRNA and protein levels were also significantly increased in the SAP group. Additionally, the expression level of sPLA₂ positively and significantly correlated with serum TNF-α and DAO levels. The extent of damage to the intestinal barrier positively correlated with intestinal sPLA₂ expression level, thus suggesting the involvement of sPLA₂ in the process of intestinal barrier damage in SAP.

QYT, DEX and VER demonstrated the potential to reduce damage to the pancreatic and intestinal tissues. These drugs also decreased serum AMY, TNF-α, and DAO levels, the intestinal epithelial cell AI, and the expression of sPLA₂ mRNA and protein. However, the interventional effect of QYT and VER were better. Thus, administration of QYT may help reduce symptoms of intestinal paralysis. QYT is also suggested to promote the inhibition of intestinal phospholipase overexpression, the release of inflammatory mediators and toxic substances, and reduce the proliferation of intestinal bacteria and the effect of their endotoxin, which when in the blood, triggers systemic inflammation. However, the precise mechanism by which QYT protects intestinal damage is yet to be comprehensively elucidated.

DEX is commonly used clinically as an anti-inflammatory agent as it inhibits inflammation and inflammation promoters, decreases vascular permeability, and antagonizes phospholipase A₂-induced release of platelet-activating factor to ease inflammation and reduce tissue injury. This study used DEX as a reference drug to compare the therapeutic effects of QYT and VER on intestinal barrier damage during SAP progression in rats. Both experimental drugs effectively reduced the expression of sPLA₂ at the transcriptional and translational levels as compared to the reference drug, and offered superior therapeutic effect against the extent of intestinal barrier damage. Preliminary results (data not shown) indicated that sPLA₂ expression was significantly higher in intestinal mucosa than in the lung tissue of SAP rats. Thus, suggesting that the role of sPLA₂ in intestinal barrier injury deserves attention.

Six hours post-operation and drug administration, the vitality of the rats in a descending order was in the DEX, QYT, and VER groups. However, 24 h post-operation, vitality was superior and disease progression was also gentler in the QYT and VER groups compared with the DEX group. The onset of QYT therapeutic effect, although slower, persisted longer compared with DEX. QYT has been widely used in clinical settings, particularly for the treatment of SAP and lung injury. Acute pancreatitis is currently diagnosed based on clinical staging, disease evolution, and other characteristics. Its treatment may be greatly enhanced if Western orthodox medicine is combined with traditional medicinal preparations, such as QYT, for a synergistic therapeutic effect, and also to ameliorate some of the commonly associated complications, including intestinal barrier injury.

### Table 2  Correlation analysis of secreted phospholipase A₂ with serum diamine oxidase and tumor necrosis factor-α levels, and apoptosis index

<table>
<thead>
<tr>
<th>Statistic</th>
<th>DAO</th>
<th>TNF-α</th>
<th>AI</th>
</tr>
</thead>
<tbody>
<tr>
<td>r</td>
<td>0.893</td>
<td>0.893</td>
<td>0.926</td>
</tr>
<tr>
<td>P-value</td>
<td>&lt; 0.05</td>
<td>&lt; 0.05</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

TNF: Tumor necrosis factor; DAO: Diamine oxidase; AI: Apoptosis index.

### COMMENTS

#### Background

Severe acute pancreatitis (SAP) can lead to the early death of patients because of associated systemic inflammatory response syndrome and multiple organ dysfunction syndromes. However, its pathogenesis has not been fully elucidated, which has impaired the development and availability of specific clinical treatments to date.

#### Research frontiers

It is currently recognized that intestinal barrier injury is the initiating factor for SAP-associated multiple organ failure.

#### Innovations and breakthroughs

The therapeutic function of the traditional Chinese medicine, Qingyi decoction, was comparable to the Western orthodox drug verapamil in a rat model of SAP. Qingyi decoction, although slower in onset of action, effectively inhibited the overexpression of secreted phospholipase A₂ (sPLA₂), which is known to play an essential pathologic role in the development of intestinal barrier injury, a common complication in SAP.

#### Applications

The intestinal transcription and protein expression levels of sPLA₂ positively correlated with the serum levels of proinflammatory factors tumor necrosis factor-α and diamine oxidase, and therefore, may be of diagnostic and/or prognostic significance in SAP disease.

#### Peer-review

SAP remains a serious clinical problem with significant morbidity and mortality. Studies suggest that loss of the gut barrier function is instrumental in the local and systemic infectious complications associated with a severe course of the disease. Improvement of intestinal barrier function may be a useful strategy to alleviate the severity and possibility of infectious complication in SAP. This study explored the involvement of sPLA₂ in intestinal barrier injury in SAP, and the intervening role of Qingyi decoction and verapamil in comparison with dexamethasone as a reference treatment. Qingyi decoction is a traditional Chinese prescription in treatment of SAP. This study is interesting and important to the field.

### REFERENCES


**P- Reviewer**: Pezzilli R, Urganci N, Xu CF, Yago Maria D  
**S- Editor**: Yu J  
**L- Editor**: AmEditor  
**E- Editor**: Zhang DN